BRAF and malignant colon neoplasm: In patients from the GEO dataset, BRAF mutation colon cancer also had higher expressions of CTLA-4 (p = 0.031) and LAG-3 (p = 0.0011), but had no significant expression of PD-1 (p = 0.58) (Figures 7F–H).